Analyst Rating Update on Pfizer (PFE)

Pfizer (PFE) : 14 analysts are covering Pfizer (PFE) and their average rating on the stock is 1.86, which is read as a Buy. 8 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 6 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Pfizer (PFE) : 13 investment research analysts covering Pfizer (PFE) have an average price target of $39.35 for the near short term. The highest target price given by the Brokerage Firm to the stock is $54 and the lowest target is $33 for the short term. Analysts expect the variance to be within $5.6 of the average price.

For the current week, the company shares have a recommendation consensus of Buy. Also, Equity Analysts at the Jefferies maintains the rating on Pfizer (NYSE:PFE). The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency raises the price target from $40 per share to $41.5 per share. The rating by the firm was issued on July 14, 2016.


Pfizer (NYSE:PFE): The stock opened at $35.91 on Wednesday but the bulls could not build on the opening and the stock topped out at $35.95 for the day. The stock traded down to $35.06 during the day, due to lack of any buying support eventually closed down at $35.29 with a loss of -2.22% for the day. The stock had closed at $36.09 on the previous day. The total traded volume was 42,635,686 shares.

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its products include Lyrica, the Prevnar family of products, Enbrel, Celebrex, Lipitor, Viagra, Zyvox, Sutent, EpiPen, Toviaz, Tygacil, Rapamune, Xalkori, Inlyta, Norvasc, BeneFIX, Genotropin and Enbrel, among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP), Global Vaccines, Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing, registering and commercializing medications in therapeutic areas, such as inflammation, cardiovascular/metabolic, neuroscience and pain, rare diseases and womens/mens health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira, Inc.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.